Clinical trial / 2012
Berberis vulgaris fruit extract improved lipid profiles, glycemic markers, and antioxidant capacity in type 2 diabetic patients.
In a double-blind trial, 31 diabetic patients were randomized to receive 3 g/d Berberis vulgaris fruit extract (BVFE) or placebo for 3 months. Compared with placebo, the BVFE group showed significant decreases in serum TG (p = 0.0001), TC (p = 0.001), LDL-c (p = 0.001), apoB (p = 0.001), glucose (p = 0.002), insulin (p = 0.01), and insulin resistance (p = 0.01), along with a significant increase in TAC (p = 0.005). Homocysteine, HbA1c, and HDL-c showed no significant differences between groups at the end of the study.
- Study type
- Double-blind randomized controlled trial
- Who was studied
- 31 type 2 diabetic patients
- What was measured
- Serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control, and total antioxidant capacity (TAC)
THE PAPER
The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients.
Shidfar F, Ebrahimi SS, Hosseini S, Heydari I, Shidfar S, Hajhassani G. Iran J Pharm Res, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.